Clinical Trial With a Depigmented, Polymerized Mite Mixture Extract at Maximum Concentrations
Immunity, Inflammation and Disease · 2024
DOI: 10.1002/iid3.70090 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Carmen Vidal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Complejo Hospitalario de Santiago, Santiago de Compostela, Spain. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Antigens, Dermatophagoides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LETI Pharma sponsored this study..
Abstract (Originalsprache)
Background
Efficacy of allergen immunotherapy is dose‐dependent; however, high doses of allergen may imply a greater risk of adverse reactions.
Objective
To assess the safety and tolerability of subcutaneous immunotherapy (SCIT) with mixtures of mite allergen extracts, Dermatophagoides pteronyssinus / Blomia tropicalis (Dpt/Bt) and Dermatophagoides pteronyssinus / Lepidoglyphus destructor (Dpt/Ld) at maximum concentrations, in adult patients with allergic rhinitis or rhinoconjunctivitis, and controlled allergic asthma due to a clinically relevant sensitisation to these mites.
Methods
An open‐label, noncontrolled, nonrandomised, phase IIb clinical trial was carried out in three hospitals in Spain between September 2014 and May 2018. Patients received SCIT of either Dpt/Bt (100/1000 DPP/mL) or Dpt/Ld (100/100 DPP/mL) in two phases: a rush build‐up phase on the first day (0.2 mL and 0.3 mL with a 30‐min interval) and a monthly maintenance phase administration (0.5 mL) up to 48 months.
Results
Forty patients were recruited for the study, seven allocated to the Dpt/Bt group and 33 to the Dpt/Ld. None experienced immediate or delayed systemic Grade ≥ 2 reactions (EAACI classification) (systemic reactions were mostly Grade 1) nor died during the study. Local reactions were mostly mild (0‒10 cm). Thirty‐nine patients (97.5%) experienced at least one adverse event (AE). Of the 283 reported AEs, eight (2.8%) were systemic reactions experienced by six (15%) subjects and 14 (4.9%) were local reactions sustained by ten (25%) subjects.
Conclusions
SCIT treatment of patients with allergic rhinitis or rhinoconjunctivitis and controlled asthma with mixtures of Dpt/Bt and Dpt/Ld allergen extracts at maximum concentrations showed a favourable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Complejo Hospitalario de Santiago, Santiago de Compostela, Spain.
- Hospital Lucus Augusti, Lugo, Spain.
- Hospital Universitario de La Candelaria, Santa Cruz de Tenerife, Spain.
- Medical Affairs and Clinical Department, LETI Pharma S.L.U., Madrid, Spain.
ORCID-Profile: Mónica Ruiz-Garcia
Förderung
- LETI Pharma sponsored this study.
Zitieren
APA
Vidal, C., Romero, L., Lopez-Freire, S., Carballada-Gonzalez, F., Garcia-Robaina, J. C., Gonzalez-Fernandez, T., Mendez-Brea, P., Nieto, E., & Ruiz-Garcia, M. (2024). Clinical Trial With a Depigmented, Polymerized Mite Mixture Extract at Maximum Concentrations. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70090
Vancouver
Vidal C, Romero L, Lopez-Freire S, Carballada-Gonzalez F, Garcia-Robaina JC, Gonzalez-Fernandez T, et al. Clinical Trial With a Depigmented, Polymerized Mite Mixture Extract at Maximum Concentrations. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.70090
BibTeX
@article{Vidal2024,
author = {Vidal, Carmen and Romero, Laura and Lopez-Freire, Sara and Carballada-Gonzalez, Francisco and Garcia-Robaina, José Carlos and Gonzalez-Fernandez, Teresa and Mendez-Brea, Paula and Nieto, Eva and Ruiz-Garcia, Mónica},
title = {Clinical Trial With a Depigmented, Polymerized Mite Mixture Extract at Maximum Concentrations},
journal = {Immunity, Inflammation and Disease},
year = {2024},
doi = {10.1002/iid3.70090}
}
EUVIMED